Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2008

01.05.2008 | Gastrointestinal Oncology

Clinical Significance of BMP7 in Human Colorectal Cancer

verfasst von: Kazuo Motoyama, MD, Fumiaki Tanaka, MD, PhD, Yoshimasa Kosaka, MD, Koshi Mimori, MD, PhD, Hiroyuki Uetake, MD, PhD, Hiroshi Inoue, MD, PhD, Kenichi Sugihara, MD, PhD, Masaki Mori, MD, PhD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Bone morphogenetic proteins (BMPs) are secreted signaling molecules belonging to the transforming growth factor (TGF)-β superfamily. Recent studies demonstrated that the expression patterns of BMPs are altered in several tumors. The purpose of the current study was to examine the expression of BMP7 in malignant and normal colorectal tissues, and to analyze whether BMP7 expression levels correlate with clinicopathological variables and prognosis in colorectal cancer.

Methods

Paired colorectal tissue samples from cancer and corresponding nonmalignant tissues were obtained from 65 patients who underwent surgical resection for colorectal cancer. The expression status of BMP7 mRNA was investigated by quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) and protein expression was analyzed by an immunohistochemical study.

Results

Quantitative real-time RT-PCR showed that BMP7 mRNA expression in cancerous tissue was significantly higher than that in normal tissue (p < 0.0001). An immunohistochemical study revealed that BMP7 was predominantly expressed in cancer cells. Elevated BMP7 expression was significantly correlated with depth of tumor invasion, liver metastasis, liver recurrence, advanced Dukes’ classification, and cancer-related death (p < 0.05, 0.001, 0.01, 0.05 and 0.01, respectively). Furthermore, patients with the highest levels of BMP7 expression showed the poorest prognosis (p < 0.01). A multivariate analysis showed that BMP7 expression status was an independent prognostic factor of overall survival (relative risk, 2.29; 95% confidence interval, 1.08–5.30; p < 0.05).

Conclusions

Expression of BMP7 in colorectal tumors correlates with parameters of pathological aggressiveness such as liver metastasis and poor prognosis. Thus, BMP7 could be a useful clinical marker for colorectal cancer patients.
Literatur
1.
Zurück zum Zitat Messerini L, Cianchi F, Cortesini C, et al. Incidence and prognostic significance of occult tumor cells in lymph nodes from patients with stage IIA colorectal carcinoma. Hum Pathol 2006;37:1259–67.PubMedCrossRef Messerini L, Cianchi F, Cortesini C, et al. Incidence and prognostic significance of occult tumor cells in lymph nodes from patients with stage IIA colorectal carcinoma. Hum Pathol 2006;37:1259–67.PubMedCrossRef
2.
Zurück zum Zitat Shih W, Chetty R, Tsao MS. Expression profiling by microarrays in colorectal cancer (Review). Oncol Rep 2005;13:517–24.PubMed Shih W, Chetty R, Tsao MS. Expression profiling by microarrays in colorectal cancer (Review). Oncol Rep 2005;13:517–24.PubMed
3.
Zurück zum Zitat Tsukuma H, Ajiki W, Oshima A. [Cancer incidence in Japan]. Gan To Kagaku Ryoho 2004;31:840–6.PubMed Tsukuma H, Ajiki W, Oshima A. [Cancer incidence in Japan]. Gan To Kagaku Ryoho 2004;31:840–6.PubMed
4.
5.
Zurück zum Zitat Roberts RB, Arteaga CL, Threadgill DW. Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell 2004;5:115–20.PubMedCrossRef Roberts RB, Arteaga CL, Threadgill DW. Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell 2004;5:115–20.PubMedCrossRef
6.
Zurück zum Zitat Ohmachi T, Tanaka F, Mimori K, et al. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006;12:3057–63.PubMedCrossRef Ohmachi T, Tanaka F, Mimori K, et al. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006;12:3057–63.PubMedCrossRef
7.
Zurück zum Zitat Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003;9:931–46.PubMed Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003;9:931–46.PubMed
8.
Zurück zum Zitat Ichikawa Y, Ishikawa T, Takahashi S, et al. Identification of genes regulating colorectal carcinogenesis by using the algorithm for diagnosing malignant state method. Biochem Biophys Res Commun 2002;296:497–506.PubMedCrossRef Ichikawa Y, Ishikawa T, Takahashi S, et al. Identification of genes regulating colorectal carcinogenesis by using the algorithm for diagnosing malignant state method. Biochem Biophys Res Commun 2002;296:497–506.PubMedCrossRef
9.
Zurück zum Zitat Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 1998;9:49–61.PubMedCrossRef Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 1998;9:49–61.PubMedCrossRef
10.
12.
Zurück zum Zitat Celeste AJ, Iannazzi JA, Taylor RC, et al. Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci USA 1990;87:9843–7.PubMedCrossRef Celeste AJ, Iannazzi JA, Taylor RC, et al. Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci USA 1990;87:9843–7.PubMedCrossRef
13.
Zurück zum Zitat Miyazono K, Kusanagi K, Inoue H. Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 2001;187:265–76.PubMedCrossRef Miyazono K, Kusanagi K, Inoue H. Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 2001;187:265–76.PubMedCrossRef
14.
15.
Zurück zum Zitat Graff JM. Embryonic patterning: to BMP or not to BMP, that is the question. Cell 1997;89:171–4.PubMedCrossRef Graff JM. Embryonic patterning: to BMP or not to BMP, that is the question. Cell 1997;89:171–4.PubMedCrossRef
16.
Zurück zum Zitat Ebendal T, Bengtsson H, Soderstrom S. Bone morphogenetic proteins and their receptors: potential functions in the brain. J Neurosci Res 1998;51:139–46.PubMedCrossRef Ebendal T, Bengtsson H, Soderstrom S. Bone morphogenetic proteins and their receptors: potential functions in the brain. J Neurosci Res 1998;51:139–46.PubMedCrossRef
17.
Zurück zum Zitat Wozney JM. The bone morphogenetic protein family: multifunctional cellular regulators in the embryo and adult. Eur J Oral Sci 1998;106:160–6.PubMed Wozney JM. The bone morphogenetic protein family: multifunctional cellular regulators in the embryo and adult. Eur J Oral Sci 1998;106:160–6.PubMed
18.
Zurück zum Zitat Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 1997;76:531–6.PubMed Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 1997;76:531–6.PubMed
19.
Zurück zum Zitat Mori M, Mimori K, Yoshikawa Y, et al. Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery 2002;131:S39–47.PubMedCrossRef Mori M, Mimori K, Yoshikawa Y, et al. Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery 2002;131:S39–47.PubMedCrossRef
20.
Zurück zum Zitat Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of elongation factor-1 delta mRNA expression in oesophageal carcinoma. Br J Cancer 2004;91:282–6.PubMedCrossRef Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of elongation factor-1 delta mRNA expression in oesophageal carcinoma. Br J Cancer 2004;91:282–6.PubMedCrossRef
21.
Zurück zum Zitat Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–70.PubMed Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–70.PubMed
22.
Zurück zum Zitat Gobbi G, Sangiorgi L, Lenzi L, et al. Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol 2002;20:143–7.PubMed Gobbi G, Sangiorgi L, Lenzi L, et al. Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol 2002;20:143–7.PubMed
23.
Zurück zum Zitat Rothhammer T, Poser I, Soncin F, et al. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 2005;65:448–56.PubMed Rothhammer T, Poser I, Soncin F, et al. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 2005;65:448–56.PubMed
24.
Zurück zum Zitat Alarmo EL, Rauta J, Kauraniemi P, et al. Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer 2006;45:411–9.PubMedCrossRef Alarmo EL, Rauta J, Kauraniemi P, et al. Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer 2006;45:411–9.PubMedCrossRef
25.
Zurück zum Zitat Alarmo EL, Kuukasjarvi T, Karhu R, et al. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res Treat 2006. Alarmo EL, Kuukasjarvi T, Karhu R, et al. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res Treat 2006.
26.
Zurück zum Zitat Masuda H, Fukabori Y, Nakano K, et al. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 2003;54:268–74.PubMedCrossRef Masuda H, Fukabori Y, Nakano K, et al. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 2003;54:268–74.PubMedCrossRef
27.
Zurück zum Zitat Hibbs K, Skubitz KM, Pambuccian SE, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 2004;165:397–414.PubMed Hibbs K, Skubitz KM, Pambuccian SE, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 2004;165:397–414.PubMed
28.
Zurück zum Zitat Sunde JS, Donninger H, Wu K, et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-{beta} signaling in ovarian cancer. Cancer Res 2006;66:8404–12.PubMedCrossRef Sunde JS, Donninger H, Wu K, et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-{beta} signaling in ovarian cancer. Cancer Res 2006;66:8404–12.PubMedCrossRef
29.
Zurück zum Zitat Bobinac D, Maric I, Zoricic S, et al. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croat Med J 2005;46:389–96.PubMed Bobinac D, Maric I, Zoricic S, et al. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croat Med J 2005;46:389–96.PubMed
30.
Zurück zum Zitat Sulzbacher I, Birner P, Trieb K, et al. The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol 2002;55:381–5.PubMed Sulzbacher I, Birner P, Trieb K, et al. The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol 2002;55:381–5.PubMed
31.
Zurück zum Zitat Yang S, Zhong C, Frenkel B, et al. Diverse biological effect and SMAD signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 2005;65:5769–77.PubMedCrossRef Yang S, Zhong C, Frenkel B, et al. Diverse biological effect and SMAD signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 2005;65:5769–77.PubMedCrossRef
32.
Zurück zum Zitat Deng H, Makizumi R, Ravikumar TS, et al. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res 2007. Deng H, Makizumi R, Ravikumar TS, et al. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res 2007.
33.
Zurück zum Zitat Grijelmo C, Rodrigue C, Svrcek M, et al. Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal 2007;19:1722–32.PubMedCrossRef Grijelmo C, Rodrigue C, Svrcek M, et al. Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal 2007;19:1722–32.PubMedCrossRef
34.
Zurück zum Zitat Pessaux P, Lermite E, Brehant O, et al. Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 2006;93:1–7.PubMedCrossRef Pessaux P, Lermite E, Brehant O, et al. Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 2006;93:1–7.PubMedCrossRef
35.
Zurück zum Zitat Talbot IC, Ritchie S, Leighton MH, et al. The clinical significance of invasion of veins by rectal cancer. Br J Surg 1980;67:439–42.PubMedCrossRef Talbot IC, Ritchie S, Leighton MH, et al. The clinical significance of invasion of veins by rectal cancer. Br J Surg 1980;67:439–42.PubMedCrossRef
36.
Zurück zum Zitat Minsky BD, Mies C, Rich TA, et al. Potentially curative surgery of colon cancer: the influence of blood vessel invasion. J Clin Oncol 1988;6:119–27.PubMed Minsky BD, Mies C, Rich TA, et al. Potentially curative surgery of colon cancer: the influence of blood vessel invasion. J Clin Oncol 1988;6:119–27.PubMed
37.
Zurück zum Zitat Inoue T, Mori M, Shimono R, et al. Vascular invasion of colorectal carcinoma readily visible with certain stains. Dis Colon Rectum 1992;35:34–9.PubMedCrossRef Inoue T, Mori M, Shimono R, et al. Vascular invasion of colorectal carcinoma readily visible with certain stains. Dis Colon Rectum 1992;35:34–9.PubMedCrossRef
38.
Zurück zum Zitat Beck SE, Jung BH, Fiorino A, et al. Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 2006;291:G135–45.PubMedCrossRef Beck SE, Jung BH, Fiorino A, et al. Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 2006;291:G135–45.PubMedCrossRef
Metadaten
Titel
Clinical Significance of BMP7 in Human Colorectal Cancer
verfasst von
Kazuo Motoyama, MD
Fumiaki Tanaka, MD, PhD
Yoshimasa Kosaka, MD
Koshi Mimori, MD, PhD
Hiroyuki Uetake, MD, PhD
Hiroshi Inoue, MD, PhD
Kenichi Sugihara, MD, PhD
Masaki Mori, MD, PhD, FACS
Publikationsdatum
01.05.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9746-4

Weitere Artikel der Ausgabe 5/2008

Annals of Surgical Oncology 5/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.